An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report

• Published in: Journal of clinical lipidology Vol. 8; no. 1; pp. 29 - 60
• Main Authors: Grundy, Scott M., Arai, Hidenori, Barter, Philip, Bersot, Thomas P., Betteridge, D. John, Carmena, Rafael, Cuevas, Ada, Davidson, Michael H., Genest, Jacques, Kesäniemi, Y. Antero, Sadikot, Shaukat, Santos, Raul D., Susekov, Andrey V., Sy, Rody G., LaleTokgözoglu, S., Watts, Gerald F., Zhao, Dong
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.01.2014
• Subjects: Anticholesteremic Agents - therapeutic use; Atherosclerosis - drug therapy; Cardiovascular; Cholesterol; Dyslipidemia; Dyslipidemias - drug therapy; Dyslipidemias - prevention & control; Health Planning Guidelines; Humans; Internationality; Life Style; Lifestyle therapies; Lifetime risk; Metabolic syndrome; Risk Factors; Societies, Medical; Statins; Lifestyle therapies; Lifetime risk; Metabolic syndrome; Cholesterol; Statins; Dyslipidemia
• ISSN: 1933-2874; 1876-4789
• DOI: 10.1016/j.jacl.2013.12.005

Abstract An international panel of the International Atherosclerosis Society has developed a new set of recommendations for the management of dyslipidemia. The panel identifies non-high-density lipoprotein cholesterol as the major atherogenic lipoprotein. Primary and secondary prevention are considered separately. Optimal levels for atherogenic lipoproteins are derived for the two forms of prevention. For primary prevention, the recommendations emphasize lifestyle therapies to reduce atherogenic lipoproteins; drug therapy is reserved for subjects at greater risk. Risk assessment is based on estimation of lifetime risk according to differences in baseline population risk in different nations or regions. Secondary prevention emphasizes use of cholesterol-lowering drugs to attain optimal levels of atherogenic lipoproteins.